HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.

AbstractBACKGROUND:
The purpose of this study was to investigate the prevalence of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) in affective disordered patients treated with lithium and to study the association of these symptoms with medication and other factors.
METHODS:
This cross-sectional study was carried out in all consenting outpatients attending an affective disorders clinic in a psychiatric hospital. The study sample consisted of 130 stable outpatients: 110 with bipolar disorder, 18 with unipolar (major) depression, and 2 with atypical affective disorder. At the time of evaluation, 110 patients were receiving lithium, 37 in combination with antidepressants and 19 with neuroleptics, and 40 had a history of neuroleptic treatment during the previous 6 months. The patients were assessed with the Extrapyramidal Symptom Rating Scale (ESRS) for parkinsonism, akathisia, dystonia, and TD. The prevalence of these symptoms was calculated for all patients and by current lithium and neuroleptic intake. Multiple linear regression analysis was used to investigate the relationship between the ESRS subscale scores and gender, age, diagnosis, and medication type.
RESULTS:
The prevalence of tremor was 20.8%; hypokinetic parkinsonism, 7.7%; akathisia, 4.6%; dystonia, 3.8%; and TD, 9.2%. Tremor was associated with lithium and neuroleptic intake; hypokinesia was associated with neuroleptic treatment and age; and TD was associated with neuroleptic, lithium, and tricyclic intake and age. Seven of 51 patients taking lithium but without a history of neuroleptic treatment during the previous 6 months presented symptoms of TD.
CONCLUSION:
The combination of lithium and neuroleptics was associated with a high prevalence of EPS. The presence of TD in lithium-treated patients not treated with neuroleptics for at least 6 months is consistent with the hypothesis that lithium may exacerbate the vulnerability of affective disordered patients to dyskinesias.
AuthorsA M Ghadirian, L Annable, M C Bélanger, G Chouinard
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 57 Issue 1 Pg. 22-8 (Jan 1996) ISSN: 0160-6689 [Print] United States
PMID8543543 (Publication Type: Journal Article)
Chemical References
  • Antipsychotic Agents
  • Lithium
Topics
  • Adult
  • Aged
  • Ambulatory Care
  • Antipsychotic Agents (therapeutic use)
  • Bipolar Disorder (drug therapy, psychology)
  • Cross-Sectional Studies
  • Depressive Disorder (drug therapy, psychology)
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced (epidemiology, etiology)
  • Female
  • Humans
  • Lithium (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Mood Disorders (drug therapy)
  • Parkinson Disease, Secondary (chemically induced, epidemiology)
  • Prevalence
  • Psychiatric Status Rating Scales
  • Regression Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: